2[1]Pinho MG, Filipe SR, Lencastre H, et al. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus[J]. J Bacteriol, 2001, 183(22): 6525-6531.
3[2]Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of microorganisms in hospitals[J]. JAMA, 1996, 275(3): 234.
4[5]Krcmery V, Sykora P, Trupl J, et al. Antibiotic use and development of resistance in blood culture isolates: 8 years of experience from a cancer referral center[J]. J Chemother, 2001, 13(2): 133-142.
5[6]Rojas H, Fernandez LN, Espino HM, et al. Patterns of drug resistance in Staphylococcus aureus from human clinical isolates[J]. Rev Cubana Med Trop, 2001, 53(1): 53-58.
6Gootz TD, Zaniewski RP, Haskell SL, et al. Activities of trovaf loxacin compar ed with those of other fluoroquinlones against purified topoisomerases and gy rA and grlA mutants of Staphylococcus aureus[J]. Antimicrob Agents Chemother, 1999, 43(8): 1845-1855.
7Yamagishi A, Kojima T, Oyamada Y, et al. Alterations in the DNA to poisomerase Ⅳ grlA gene responsible for quinolone resistance in Staphylococcus aureus[J]. Antimicrob Agents Chemother,1996,40(5):1157-1163.
8Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus[J ]. Antimicrob Agents Chemother, 1995, 39(7): 1554-1558.
9Shen LL, Mitscher LA, Sharma PN, et al. Mechanism of inhibition of DNA gyras e by quinolone antibacterials: a cooperative drug-DNA binding model[J]. Biochemistry, 1989, 28(9): 3889-3894.
10Ito H, Yoshida H, Bogaki-Shonai M, et al. Quinolone resistance mu tations in th e DNA gyrase gyrA and gyrB genes of Staphylococcus aureus[J]. Antimicrob Agents Chemother, 1994, 38(9): 2014-2023.
